EGF-Rich Exosomes via Mesenchymal Stem Cell Genetic Editing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing exosomes secreted by mesenchymal stem cells contain very low levels of Epidermal Growth Factor (EGF), making them ineffective for therapeutic applications, particularly in wound healing and tissue repair.

Innovation Solution

Genetic editing of mesenchymal stem cells to enhance their ability to synthesize and secrete EGF, resulting in exosomes with a significantly increased EGF content, up to more than 35 times the original level.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If exosomes are used to deliver EGF for wound healing, then therapeutic effect is improved, but EGF content in exosomes is insufficient

Engineering Contradiction:

Improvetherapeutic effectVSAvoidEGF content

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent changes the physiological state parameters of mesenchymal stem cells by inducing differentiation into osteogenic direction, which fundamentally alters the cellular machinery to produce and package significantly higher amounts of EGF into exosomes, resolving the contradiction between exosome therapeutic potential and EGF content insufficiency

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent performs preliminary differentiation of mesenchymal stem cells into osteogenic lineage before exosome production, pre-establishing the cellular framework and enzymatic machinery necessary for high-level EGF synthesis and packaging, thereby ensuring sufficient EGF content in the resulting exosomes

Inventive Principle:

Principle #10Preliminary action

2Productivity

If wild-type mesenchymal stem cells are used, then cell availability is high, but EGF synthesis and secretion ability is insufficient

Engineering Contradiction:

Improvecell availabilityVSAvoidEGF synthesis and secretion

Core Design Contradiction:

ProductivityVSQuantity of substance

Solution Approach 1:

The patent changes the functional state parameters of mesenchymal stem cells by inducing osteogenic differentiation, which fundamentally alters the cellular machinery to produce and package significantly higher amounts of EGF, resolving the contradiction between cell availability and EGF synthesis capability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies local quality enhancement by selectively inducing osteogenic differentiation in specific cell populations, creating a subset of cells with enhanced EGF production capacity while maintaining the overall availability and accessibility of mesenchymal stem cells for therapeutic applications

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20250121031A1EGF-rich exosomes, preparation method and use thereof

Publication Date: 2025.04.17 CENTRE FOR REGENERATIVE MEDICINE & HEALTH HONG KONG INSTITUTE OF SCIENCE & INNOVATION CHINESE ACADEMY OF SCIENCES

AI summary

The disclosure provides an exosome. The exosome contains Epidermal Growth Factors (EGF) with increased content. The disclosure also provides a preparation method for the exosome. The exosome can be used for the treatment of EGF-related diseases, such as repair and healing of wound surfaces caused by corneal injury, burns, scalds, ulcers, surgeries and the like, and can be used for the prevention of scar hyperplasia.